Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of resected non-small-cell lung cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3907

Provisional Schedule

Committee meeting 07 August 2024
Expected publication 16 October 2024

Project Team

Project lead Celia Mayers

Email enquiries

Stakeholders

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Asthma and Lung UK
  Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  Association of Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Interventional Radiology
  British Thoracic Oncology Group
  British Thoracic Society
  British Transplantation Society
  Cancer Research UK
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  NHS Blood and Transplant
  Primary Care Respiratory Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Aspire Pharma (pemetrexed)
  Bristol Myers Squibb (paclitaxel)
  Eli Lilly (pemetrexed)
  Genus Pharmaceuticals (pemetrexed)
  Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Medac (vinorelbine)
  Pfizer (pemetrexed)
  Pierre Fabre (vinorelbine)
  Sandoz (cisplatin, pemetrexed)
  Seacross Pharmaceuticals (docetaxel, pemetrexed, paclitaxel)
  Sun Pharma (gemcitabine)
  Synchrony Pharma (gemcitabine)
  Teva UK (paclitaxel)
  Zentiva (pemetrexed)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
09 January 2024 Invitation to participate
25 August 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
18 July 2023 The scope of the first iteration of the NSCLC pathway will focus on development of the evidence synthesis of currently available data and the core model development. Therefore, ID3907, will be routed through a single technology appraisal route. More details about the NSCLC can be found on the webpage for ID6234.
27 February 2023 Please note that the evaluation of pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer ID3907, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer.
16 December 2022 Please note that following on from a further regulatory update received from the company, the timelines for this appraisal have been revised.
14 September 2022 Please note that following on from a regulatory update received from the company, the timelines for this appraisal have been revised.
14 July 2022 Invitation to participate
13 April 2022 - 13 May 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual